Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models

The aim of this study was (1) to determine how closely physiologically based pharmacokinetic (PBPK) models can predict oral bioavailability using a priori knowledge of drug‐specific properties and (2) to examine the influence of the biopharmaceutics classification system class on the simulation success.

[1]  Vikash K. Sinha,et al.  Prediction of Human Oral Plasma Concentration-Time Profiles Using Preclinical Data , 2011, Clinical pharmacokinetics.

[2]  D J Rance,et al.  The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. , 1997, The Journal of pharmacology and experimental therapeutics.

[3]  D M Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: furosemide. , 2010, Journal of pharmaceutical sciences.

[4]  J. Dressman,et al.  Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. , 2010, Journal of pharmaceutical sciences.

[5]  P. Mura,et al.  Development and evaluation of an in vitro method for prediction of human drug absorption II. Demonstration of the method suitability. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[6]  N. Kaneniwa,et al.  Study of the absorption site of cimetidine. , 1986, Journal of pharmacobio-dynamics.

[7]  G. Amidon,et al.  Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[8]  J. Polli,et al.  Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Nifedipine. , 2015, Journal of pharmaceutical sciences.

[9]  Patrick Poulin,et al.  Development of a novel method for predicting human volume of distribution at steady-state of basic drugs and comparative assessment with existing methods. , 2009, Journal of pharmaceutical sciences.

[10]  Sebastian Polak,et al.  Quantitative prediction of formulation-specific food effects and their population variability from in vitro data with the physiologically-based ADAM model: a case study using the BCS/BDDCS Class II drug nifedipine. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[11]  T Lavé,et al.  Challenges and opportunities with modelling and simulation in drug discovery and drug development , 2007, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  C. Barthélémy,et al.  Grapefruit juice–nifedipine interaction: possible involvement of several mechanisms , 2005, Journal of clinical pharmacy and therapeutics.

[13]  Kaneniwa Nobuyoshi,et al.  Discontinuous absorption property of cimetidine , 1986 .

[14]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[15]  B. Kaufmann,et al.  Pharmacokinetics of Metildigoxin and Digoxin in Geriatric Patients with Normal and Elevated Serum Creatinine Levels , 1981, Clinical pharmacokinetics.

[16]  P. Deasy,et al.  An investigation into the transdermal delivery of nifedipine. , 1996, Pharmaceutica acta Helvetiae.

[17]  Naseem A. Charoo,et al.  Biowaiver monograph for immediate-release solid oral dosage forms: bisoprolol fumarate. , 2014, Journal of pharmaceutical sciences.

[18]  A. Somogyi,et al.  Clinical Pharmacokinetics of Cimetidine , 1983, Clinical pharmacokinetics.

[19]  D. Barends,et al.  Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. , 2006, Journal of pharmaceutical sciences.

[20]  D. Shen,et al.  Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.

[21]  B Agoram,et al.  Predicting the impact of physiological and biochemical processes on oral drug bioavailability. , 2001, Advanced drug delivery reviews.

[22]  J. Sommer,et al.  Pharmacokinetics and metabolism of nifedipine. , 1983, Hypertension.

[23]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[24]  G L Amidon,et al.  A compartmental absorption and transit model for estimating oral drug absorption. , 1999, International journal of pharmaceutics.

[25]  Michael Gertz,et al.  Prediction of Human Intestinal First-Pass Metabolism of 25 CYP3A Substrates from In Vitro Clearance and Permeability Data , 2010, Drug Metabolism and Disposition.

[26]  Stefan Willmann,et al.  Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation. , 2013, Journal of pharmaceutical sciences.

[27]  Michael B Bolger,et al.  In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate. , 2012, Molecular pharmaceutics.

[28]  K Rowland-Yeo,et al.  Evaluation of an In Silico PBPK Post-Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine , 2013, CPT: pharmacometrics & systems pharmacology.

[29]  M. Rowland,et al.  Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. , 2006, Journal of pharmaceutical sciences.

[30]  R. Miller,et al.  Pharmacokinetics and bioavailability of cimetidine in humans. , 1980, Journal of pharmaceutical sciences.

[31]  Michael Levin.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2001 .

[32]  Antonello Caruso,et al.  Application of PBPK modeling to predict human intestinal metabolism of CYP3A substrates - an evaluation and case study using GastroPlus. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[33]  Rui Chen,et al.  Simulation of the pharmacokinetics of bisoprolol in healthy adults and patients with impaired renal function using whole-body physiologically based pharmacokinetic modeling , 2012, Acta Pharmacologica Sinica.

[34]  P. Carrupt,et al.  Pharmacokinetics of β-adrenoceptor blockers in obese and normal volunteers , 1997 .

[35]  J. Houston,et al.  Prediction of Human Metabolic Clearance from In Vitro Systems: Retrospective Analysis and Prospective View , 2010, Pharmaceutical Research.

[36]  P. Hinderling,et al.  Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. , 1997, Pharmacological reviews.

[37]  J. Houston,et al.  Evaluation of hepatic clearance prediction using in vitro data: emphasis on fraction unbound in plasma and drug ionisation using a database of 107 drugs. , 2012, Journal of pharmaceutical sciences.

[38]  Gordon L. Amidon,et al.  Gastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogs , 1995, Pharmaceutical Research.

[39]  D. Breimer,et al.  Nifedipine: Kinetics and dynamics in healthy subjects , 1984, Clinical pharmacology and therapeutics.

[40]  A. Forrey,et al.  Furosemide concentrations in serum and urine, and its binding by serum proteins as measured fluorometrically. , 1974, Clinical chemistry.

[41]  Jennifer B Dressman,et al.  Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products , 2006, Clinical Pharmacokinetics.

[42]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. , 2002, Journal of pharmaceutical sciences.

[43]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[44]  Structure-Based Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes , 2009, The AAPS Journal.

[45]  A. Renwick,et al.  Factors affecting the absolute bioavailability of nifedipine. , 1995, British journal of clinical pharmacology.

[46]  M. Leider.  Goodman & Gilman's The Pharmacological Basis of Therapeutics , 1985 .

[47]  Sebastian Polak,et al.  Population-Based Mechanistic Prediction of Oral Drug Absorption , 2009, The AAPS Journal.

[48]  L. Benet,et al.  Net Secretion of Furosemide Is Subject to Indomethacin Inhibition, as Observed in Caco-2 Monolayers and Excised Rat Jejunum , 1999, Pharmaceutical Research.

[49]  Erik Sjögren,et al.  In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[50]  Patrick Poulin,et al.  Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. , 2002, Journal of pharmaceutical sciences.

[51]  Malcolm Rowland,et al.  Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.

[52]  G L Amidon,et al.  Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. , 1998, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  A. Galetin,et al.  Intestinal and Hepatic Metabolic Activity of Five Cytochrome P450 Enzymes: Impact on Prediction of First-Pass Metabolism , 2006, Journal of Pharmacology and Experimental Therapeutics.

[54]  Sarfaraz K. Niazi.  Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System , 2004, Handbook of Pharmaceutical Manufacturing Formulations, Third Edition.

[55]  M. Rowland,et al.  Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. , 2005, Journal of pharmaceutical sciences.

[56]  W. Allum,et al.  Interaction between debrisoquine and phenylephrine in man. , 1973, British journal of clinical pharmacology.

[57]  P. Carrupt,et al.  Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. , 1997, British journal of clinical pharmacology.

[58]  Gordon L. Amidon,et al.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[59]  R. C. Moreton.  United States Pharmacopeia-National Formulary , 2016 .

[60]  Tycho Heimbach,et al.  Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds. , 2015, Journal of pharmaceutical sciences.

[61]  S. Stavchansky,et al.  Estimation of the Relative Contribution of the Transcellular and Paracellular Pathway to the Transport of Passively Absorbed Drugs in the Caco-2 Cell Culture Model , 1997, Pharmaceutical Research.

[62]  Kairui Feng,et al.  The Simcyp® Population-based ADME Simulator , 2009 .

[63]  A. Rosén,et al.  Bioavailability and pharmacokinetics of cimetidine , 1979, European Journal of Clinical Pharmacology.

[64]  G. Leopold.  Balanced Pharmacokinetics and Metabolism of Bisoprolol , 1985, Journal of cardiovascular pharmacology.

[65]  Su Young Choi,et al.  Prediction of the permeability of drugs through study on quantitative structure-permeability relationship. , 2006, Journal of pharmaceutical and biomedical analysis.

[66]  L. Paalzow,et al.  Pharmacokinetics of furosemide in man after intravenous and oral administration. Application of moment analysis , 2004, European Journal of Clinical Pharmacology.